Endocrine Abstracts

The American Thyroid Association has recently developed updated guidelines for the management of thyroid nodules and thyroid cancer. Compared to previous editions, this new guidelines give important new recommendation on several issues.Initial treatment for thyroid cancer is total thyroidectomy. After total thyroidectomy, patients are treated with 131I activities aimed at ablating any remnant thyroid tissue. Radioiodine ablation is recommended...

After total thyroidectomy, patients with differentiated thyroid cancer are treated with 131I activities aimed at ablating any remnant thyroid tissue and potential microscopic residual tumor. This procedure decreases the risk of locoregional recurrence and facilitates the long-term follow-up. In addition the high activity of 131I allows obtaining a highly sensitive post-therapeutic WBS. Radioiodine ablation is recommended in high-risk patients and in low-r...

The initial management of differentiated thyroid cancer is based on total thyroidectomy and radioiodine ablative therapy. Less radical treatment is advocate only in unifocal microcarcinomas. Following initial treatment, long term follow-up is initiated, aimed to the early discovery of persistent or recurrent disease. Follow-up strategies has changed in recent years, after the introduction in the clinical practice of neck ultrasound and recombinant human TSH (rhTSH). The drug h...

Introduction: Adrenal insufficiency is a life-threatening disease. Conventional treatment requires multiple daily doses of immediate-release hydrocortisone or cortisone acetate causing non-physiological peaks and nadir of cortisol and it has been also associated with premature mortality, high frequency of infections, reduced quality of life, altered metabolic profile and reduced bone mineral density. A modified-release hydrocortisone (Plenadren®, Shire) by combining a rap...

Abstract: Radioiodine is a definite treatment option for toxic goiter. We have evaluated volume reduction, function and autoimmunity outcomes with a 15 mCi fixed regimen. Patients with at least one US evaluation before and after Iodine-131 therapy and with at least one year of follow-up were included. TSH, free-T4, antibodies and goiter volume before and yearly after Iodine-131 treatment were analysed for the length of the entire follow-up. The total 151 patients, 72.6% female...

Background: MicroRNAs (miRNAs) are small non-protein encoding RNAs which negatively regulate gene expression. Tissue miRNA profiles may be useful to distinguish benign from malignant lesions. Recently, we have identified in the serum of a retrospective series of patients, with benign nodular goiter (n=80) and papillary thyroid cancer (PTC: n=79), two miRNAs (-190 and -95) that in combination (providing the risk of malignancy defined as pmiRNA) allow the diffe...

Introduction: MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that act as negative regulators of gene expression. The miRNA expression is impaired in many types of human cancer including thyroid cancer. The tissue profile of miRNAs has been shown to be useful for differentiating benign from malignant thyroid nodules, however attainment of tissue samples requires an invasive procedure while blood sampling is minimally invasive and easy to obtain. The aim of this study...